Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENDER: Lenalidomide and Dexamethasone in Elderly Unfit Patients with Newly Diagnosed Multiple Myeloma
NCT03809780Phase 2Active, not recruiting
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in multiple myeloma (MM). Primary endpoint: Progression-Free Survival at 2 years. Started Mar 2019; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03809780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809780.